Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why United Therapeutics ( UTHR ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today - United Therapeutics ( NASDAQ:UTHR )
United Therapeutics ( NASDAQ:UTHR ) has outperformed the market over the past 15 years by 2.35% on an annualized basis producing an average annual return of 14.5%. Currently, United Therapeutics has a market capitalization of $20.42 billion.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Why United Therapeutics ( UTHR ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is First Trust Growth Strength ETF ( FTGS ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Is United Therapeutics Corp Gaining or Losing Market Support? - United Therapeutics ( NASDAQ:UTHR )
United Therapeutics Corp's ( NYSE:UTHR ) short interest as a percent of float has fallen 7.38% since its last report. According to exchange reported data, there are now 2.03 million shares sold short, which is 5.9% of all regular shares that are available for trading.
P/E Ratio Insights for United Therapeutics - United Therapeutics ( NASDAQ:UTHR )
In the current market session, United Therapeutics Inc. ( NASDAQ:UTHR ) stock price is at $446.87, after a 1.57% drop. However, over the past month, the company's stock went up by 1.56%, and in the past year, by 11.59%.
My Top Vanguard Index ETF Pick for 2026
This ETF has underperformed the S&P 500 lately, but I think that will change.
Here's Why United Therapeutics ( UTHR ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update - MannKind ( NASDAQ:MNKD )
sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026 FUROSCIX ReadyFlow™ Autoinjector sNDA submitted to the FDA MNKD-101 NTM global Phase 3 trial ( ICoN-1 ) achieved interim enrollment target ahead of schedule
If You Invested $100 In United Therapeutics Stock 5 Years Ago, You Would Have This Much Today - United Therapeutics ( NASDAQ:UTHR )
United Therapeutics ( NASDAQ:UTHR ) has outperformed the market over the past 5 years by 12.2% on an annualized basis producing an average annual return of 26.06%. Currently, United Therapeutics has a market capitalization of $18.59 billion.
Why United Therapeutics ( UTHR ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third ...
MKKGY vs. UTHR: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA ( MKKGY Quick QuoteMKKGY - ) and United Therapeutics ( UTHR Quick QuoteUTHR - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
United Therapeutics ( UTHR ) Earnings Transcript
Image source: The Motley Fool.Wednesday, October 29, 2025, at 9 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000 - iShares Semiconductor ETF ( NASDAQ:SOXX )
A powerful surge in AI-related stocks - led by a 9% advance in NVIDIA Corp. ( NASDAQ:NVDA ) over the past two sessions - propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100 points, both breaking new records, as investors brace for the Federal Reserve's highly ...
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark
UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Axogen ( NASDAQ:AXGN ) , Bloom Energy ( NYSE:BE )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Caterpillar Inc ( NYSE:CAT ) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results.
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision oncology growth.
United Therapeutics ( UTHR ) Beats Q3 Earnings Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of +3.92% and -2.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should First Trust Growth Strength ETF ( FTGS ) Be on Your Investing Radar?
Style Box ETF report for ...
Nepsis Liquidates $14 Million CyberArk Software ( NASDAQ: CYBR ) Position: Did the Stock Soar Too High, Too Fast?
Nepsis Inc. fully exited its position in CyberArk Software ( NASDAQ:CYBR ) , selling 34,236 shares in Q3 2025 for an estimated $13.93 million, SEC filings show.According to a filing with the U.S. Securities and Exchange Commission dated October 23, 2025, Nepsis liquidated its entire holding in ...
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.
Analysts Estimate Amneal Pharmaceuticals ( AMRX ) to Report a Decline in Earnings: What to Look Out for
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics ( UTHR ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today - United Therapeutics ( NASDAQ:UTHR )
United Therapeutics ( NASDAQ:UTHR ) has outperformed the market over the past 15 years by 2.22% on an annualized basis producing an average annual return of 14.48%. Currently, United Therapeutics has a market capitalization of $19.11 billion.
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care - MannKind ( NASDAQ:MNKD )
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( NASDAQ:MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
Is IPF the Next Big Market Opportunity for United Therapeutics?
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Lyell Immunopharma ( NASDAQ:LYEL ) , First Horizon ( NYSE:FHN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.
Theravance Bio ( TBPH ) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results - Celularity ( NASDAQ:CELU ) , CARISMA Therapeutics ( NASDAQ:CARM )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 1% on Tuesday. The Dow traded down 1.08% to 45,052.65 while the NASDAQ fell 1.60% to 21,111.52. The S&P 500 also fell, dropping, 1.32% to 6,374.93. Consumer staples shares jumped by 0.1% on Tuesday.
Why Is United Therapeutics Stock Rallying On Tuesday? - United Therapeutics ( NASDAQ:UTHR )
Tyvaso improved absolute FVC by 95.6 mL over placebo at week 52 in IPF patients. United Therapeutics plans FDA talks in 2025; TETON-1 data expected by mid-2026. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special )
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Apollo Asset Management ( NYSE:APO ) , Air Lease ( NYSE:AL )
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Air Lease Corporation AL rose sharply during Tuesday's session after the aircraft lessor said it will be acquired by a newly formed Dublin-based holding company backed by Sumitomo Corp.
Why Is United Therapeutics ( UTHR ) Up 11.9% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - MannKind ( NASDAQ:MNKD ) , United Therapeutics ( NASDAQ:UTHR )
DANBURY, Conn. and BOSTON, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD today announced that United Therapeutics Corporation UTHR has exercised its option-granted under the companies' 2018 license and collaboration agreement-to develop a second dry powder inhalation therapy.
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
DANBURY, Conn. and BOSTON, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) today announced that United Therapeutics Corporation ( Nasdaq: UTHR ) has exercised its option-granted under the companies' 2018 license and collaboration agreement-to develop a second dry powder ...
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) and scPharmaceuticals Inc. ( Nasdaq: SCPH ) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases - MannKind ( NASDAQ:MNKD ) , scPharmaceuticals ( NASDAQ:SCPH )
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
• Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need • Upfront cash payment of $5.35 per share plus one non-tradable contingent ...
Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD - 3D Sys ( NYSE:DDD )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against 3D Systems Corporation ( "3D Systems" or the "Company" ) DDD and certain officers.
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Liquidia Corporation ( NASDAQ: LQDA ) , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025.
Lost Money on 3D Systems Corporation ( DDD ) ? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - 3D Sys ( NYSE:DDD )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in 3D Systems Corporation ( "3D Systems Corporation" or the "Company" ) DDD of a class action securities lawsuit.
